Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 56 articles:
HTML format



Single Articles


    January 2026
  1. LIANG X, Luo J, Zhou Q, Xin J, et al
    Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.
    Gut. 2026;75:367-381.
    PubMed     Abstract available


    December 2025
  2. HE T, Chen M, Liu M, Zhang L, et al
    Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B.
    Gut. 2025 Dec 24:gutjnl-2025-336655. doi: 10.1136/gutjnl-2025-336655.
    PubMed     Abstract available


  3. SCHWINGE D
    Hepatocyte guardian: A20 restrains ferroptosis in autoimmune hepatitis.
    Gut. 2025 Dec 24:gutjnl-2025-337347. doi: 10.1136/gutjnl-2025-337347.
    PubMed    


  4. LENS S, Burton AR, Davies J, Locatelli M, et al
    Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal.
    Gut. 2025 Dec 19:gutjnl-2024-333309. doi: 10.1136/gutjnl-2024-333309.
    PubMed     Abstract available


  5. WANG J, Zhang S, Chen Y, Fan T, et al
    Serum thrombospondin-2 as a non-invasive biomarker for liver fibrosis in chronic hepatitis B.
    Gut. 2025 Dec 17:gutjnl-2025-336665. doi: 10.1136/gutjnl-2025-336665.
    PubMed    


  6. CHU CM, Liaw YF
    Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.
    Gut. 2025 Dec 3:gutjnl-2025-337558. doi: 10.1136/gutjnl-2025-337558.
    PubMed    


    November 2025
  7. LIN C, Huang Y, Ran N, Liu J, et al
    Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-alpha.
    Gut. 2025;74:2035-2049.
    PubMed     Abstract available


  8. CHEN Y, Li W, Wang S, Wang H, et al
    A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis.
    Gut. 2025 Nov 4:gutjnl-2025-336363. doi: 10.1136/gutjnl-2025-336363.
    PubMed     Abstract available


  9. KENNEDY PTF, Fung S, Buti M, Yilmaz G, et al
    Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.
    Gut. 2025 Nov 4:gutjnl-2025-336592. doi: 10.1136/gutjnl-2025-336592.
    PubMed     Abstract available


    October 2025
  10. TANG S, Huang T, Tang R, Lin K, et al
    EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
    Gut. 2025 Oct 28:gutjnl-2025-335449. doi: 10.1136/gutjnl-2025-335449.
    PubMed     Abstract available


  11. WANG J, Fan T, Zhu L, Zhang S, et al
    Profiles of quantitative hepatitis B surface antigen in patients with chronic hepatitis B.
    Gut. 2025 Oct 23:gutjnl-2025-336924. doi: 10.1136/gutjnl-2025-336924.
    PubMed    


  12. CHUMBE AL, van den Aardweg SMD, Boyd A, Grobben M, et al
    Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.
    Gut. 2025 Oct 23:gutjnl-2025-336302. doi: 10.1136/gutjnl-2025-336302.
    PubMed     Abstract available


  13. LIU F, Liu T, Wu X, Yu Z, et al
    iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation.
    Gut. 2025 Oct 21:gutjnl-2025-336105. doi: 10.1136/gutjnl-2025-336105.
    PubMed     Abstract available


  14. HUANG R, Trinh HN, Yasuda S, Chau A, et al
    Differential HCC risk among HBV indeterminate types at baseline and by phase transition.
    Gut. 2025;74:1873-1882.
    PubMed     Abstract available


  15. XU X, Chen J, Yu X, Li Z, et al
    Single-cell analysis identifies RETN(+) monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2025 Oct 6:gutjnl-2025-335998. doi: 10.1136/gutjnl-2025-335998.
    PubMed     Abstract available


    September 2025
  16. TSENG TC, Yang HI, Kao JH
    Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.
    Gut. 2025 Sep 27:gutjnl-2025-336947. doi: 10.1136/gutjnl-2025-336947.
    PubMed    


  17. TSENG TC, Yang HI, Kao JH
    Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.
    Gut. 2025 Sep 27:gutjnl-2025-336618. doi: 10.1136/gutjnl-2025-336618.
    PubMed    


    August 2025
  18. FAN T, Wang J, Zhu C, Wu C, et al
    Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.
    Gut. 2025 Aug 24:gutjnl-2025-336520. doi: 10.1136/gutjnl-2025-336520.
    PubMed    


  19. SU CW, Liang YJ, Wu JC
    Unravelling the heterogeneous HCC risk in indeterminate chronic hepatitis B.
    Gut. 2025 Aug 18:gutjnl-2025-335915. doi: 10.1136/gutjnl-2025-335915.
    PubMed    


  20. WU X, Quan D, Li W, Wisskirchen K, et al
    Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
    Gut. 2025 Aug 12:gutjnl-2025-335456. doi: 10.1136/gutjnl-2025-335456.
    PubMed     Abstract available


  21. HUI RW, Wu TK, Ho KC, Leung RH, et al
    Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure.
    Gut. 2025 Aug 5:gutjnl-2025-335219. doi: 10.1136/gutjnl-2025-335219.
    PubMed     Abstract available


    July 2025
  22. SETO WK, Lok A
    Partial cure of chronic hepatitis B: potential implications for HCC surveillance?
    Gut. 2025 Jul 29:gutjnl-2025-336032. doi: 10.1136/gutjnl-2025-336032.
    PubMed    


  23. CHEN J, You H, Lau G
    Rethinking 'Inactive Chronic Hepatitis B': should we treat patients with high HBsAg levels?
    Gut. 2025 Jul 23:gutjnl-2025-336373. doi: 10.1136/gutjnl-2025-336373.
    PubMed    


  24. GUILLOT A, Pose E
    Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?
    Gut. 2025 Jul 17:gutjnl-2025-335271. doi: 10.1136/gutjnl-2025-335271.
    PubMed    


    June 2025
  25. TSENG TC, Huang SC, Pan MH, Liu CJ, et al
    Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold.
    Gut. 2025 Jun 20:gutjnl-2025-334911. doi: 10.1136/gutjnl-2025-334911.
    PubMed     Abstract available


    May 2025
  26. LI H, Song M, Hylemon PB, Zhou H, et al
    LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis.
    Gut. 2025 May 13:gutjnl-2025-335259. doi: 10.1136/gutjnl-2025-335259.
    PubMed    


    April 2025
  27. ROTTELE F, Zollner A, Mogler C, Yuksel M, et al
    Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19.
    Gut. 2025 Apr 5:gutjnl-2024-333880. doi: 10.1136/gutjnl-2024-333880.
    PubMed     Abstract available


  28. LURJE I, Tacke F
    Immune pathology in paediatric acute hepatitis of unknown origin - uncovering the link to COVID-19.
    Gut. 2025 Apr 5:gutjnl-2024-334453. doi: 10.1136/gutjnl-2024-334453.
    PubMed    


  29. GLEESON D, Bornand R, Brownlee A, Dhaliwal H, et al
    British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.
    Gut. 2025 Apr 1:gutjnl-2024-333171. doi: 10.1136/gutjnl-2024-333171.
    PubMed     Abstract available


    March 2025
  30. XU H, Wu Z, Qin J, Li X, et al
    Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2.
    Gut. 2025 Mar 26:gutjnl-2024-334318. doi: 10.1136/gutjnl-2024-334318.
    PubMed     Abstract available


  31. RODRIGO-TORRES D, Kilpatrick AM, Ferreira-Gonzalez S, Aird RE, et al
    Longitudinal paired liver biopsies and transcriptome profiling in alcohol-associated hepatitis reveal dynamic changes in cellular senescence.
    Gut. 2025 Mar 23:gutjnl-2024-334094. doi: 10.1136/gutjnl-2024-334094.
    PubMed     Abstract available


    December 2024
  32. LAMPERTICO P, Anolli MP, Roulot D, Wedemeyer H, et al
    Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.
    Gut. 2024 Dec 11:gutjnl-2024-332597. doi: 10.1136/gutjnl-2024-332597.
    PubMed     Abstract available


    October 2024
  33. PAN DZ, Soulette CM, Aggarwal A, Han D, et al
    Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
    Gut. 2024 Oct 8:gutjnl-2024-332526. doi: 10.1136/gutjnl-2024-332526.
    PubMed     Abstract available


  34. LIU T, Li J, Yin X, Lu F, et al
    Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system.
    Gut. 2024 Oct 1:gutjnl-2024-332784. doi: 10.1136/gutjnl-2024-332784.
    PubMed     Abstract available


    September 2024
  35. BROL MJ, Canbay A, Trebicka J
    Alcohol-associated hepatitis: a neutrophile disease?
    Gut. 2024 Sep 24:gutjnl-2024-333222. doi: 10.1136/gutjnl-2024-333222.
    PubMed    


  36. MAK LY, Wooddell CI, Lenz O, Schluep T, et al
    Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989.
    Gut. 2024 Sep 12:gutjnl-2024-333026. doi: 10.1136/gutjnl-2024-333026.
    PubMed     Abstract available


  37. FAN R, Zhao S, Niu J, Ma H, et al
    High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy.
    Gut. 2024;73:1725-1736.
    PubMed     Abstract available


    July 2024
  38. VECCHI A, Rossi M, Tiezzi C, Fisicaro P, et al
    HBcrAg values may predict virological and immunological responses to pegIFN-alpha in NUC-suppressed HBeAg-negative chronic hepatitis B.
    Gut. 2024 Jul 20:gutjnl-2024-332290. doi: 10.1136/gutjnl-2024-332290.
    PubMed     Abstract available


  39. KREIMEYER H, Gonzalez CG, Fondevila MF, Hsu CL, et al
    Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
    Gut. 2024 Jul 20:gutjnl-2024-332730. doi: 10.1136/gutjnl-2024-332730.
    PubMed     Abstract available


  40. BAUMERT T, Urbanek-Quaing M, Cornberg M
    Immunomodulation and entry inhibition: selgantolimod's double punch against hepatitis B virus.
    Gut. 2024 Jul 5:gutjnl-2024-332679. doi: 10.1136/gutjnl-2024-332679.
    PubMed    


  41. KAMAR N, Marion O, Abravanel F, Esposito L, et al
    Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?
    Gut. 2024 Jul 2:gutjnl-2024-332744. doi: 10.1136/gutjnl-2024-332744.
    PubMed    


    June 2024
  42. ZHOU J, Liu K, Pan Q
    Porcine-derived pancreatic enzyme replacement therapy linking to chronic hepatitis E: broad implications.
    Gut. 2024 Jun 12:gutjnl-2024-332975. doi: 10.1136/gutjnl-2024-332975.
    PubMed    


    May 2024
  43. FRERICKS N, Kinast V, Steinmann E
    Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus.
    Gut. 2024 May 31:gutjnl-2024-332577. doi: 10.1136/gutjnl-2024-332577.
    PubMed    


  44. VO-QUANG E, Pawlotsky JM
    'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.
    Gut. 2024 May 23:gutjnl-2024-332177. doi: 10.1136/gutjnl-2024-332177.
    PubMed     Abstract available


  45. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    PubMed     Abstract available


    April 2024
  46. THORNTON CS, Waddell BJ, Congly SE, Svishchuk J, et al
    Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
    Gut. 2024 Apr 15:gutjnl-2023-330602. doi: 10.1136/gutjnl-2023-330602.
    PubMed     Abstract available


    January 2024
  47. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    PubMed    



  48. Correction: Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2024;73:e1.
    PubMed    


  49. LIN C, Luo L, Xun Z, Zhu C, et al
    Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection.
    Gut. 2024;73:338-349.
    PubMed     Abstract available


    November 2023
  50. WANG Y, Li Q, Li C, Wang C, et al
    Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion.
    Gut. 2023 Nov 16:gutjnl-2023-330537. doi: 10.1136/gutjnl-2023-330537.
    PubMed     Abstract available


  51. YU X, Gong Q, Yu D, Chen Y, et al
    Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
    Gut. 2023 Nov 15:gutjnl-2023-330577. doi: 10.1136/gutjnl-2023-330577.
    PubMed     Abstract available


    October 2023
  52. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    PubMed     Abstract available


  53. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available


  54. LIU Z, Lin C, Mao X, Guo C, et al
    Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.
    Gut. 2023 Oct 5:gutjnl-2023-330691. doi: 10.1136/gutjnl-2023-330691.
    PubMed     Abstract available


    September 2023
  55. LE BERT N, Fisicaro P
    Enolase: a metabolic checkpoint behind diverse exhaustion stages of CD8+ T cells in chronic HBV and HCV.
    Gut. 2023 Sep 6:gutjnl-2023-330541. doi: 10.1136/gutjnl-2023-330541.
    PubMed    


    January 2023
  56. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.